Ovarian cancer is the fifth leading cause of cancer death in women and one of the most difficult malignancies to detect at an early stage.
Emerging clinical evidence suggests that the enzyme cyclooxygenase-1 (COX-1) contributes significantly to tumorigenesis in ovarian cancer. Thus COX-1 could serve as a novel target for molecular imaging probes to improve early detection and response to treatment.
Now in the American Chemical Society journal ACS Omega, Md. Jashim Uddin, Ph.D., Lawrence Marnett, Ph.D., and colleagues report the discovery of FDF, a furanone-based novel COX-1 selective inhibitor with adequate properties to enable its use for in vivo imaging.
In two distinct animal models of ovarian cancer, xenografts expressing high levels of COX-1 demonstrated targeted uptake of the compound containing the F-18 radioisotope (18F-FDF) compared to tissues expressing low protein levels.
This indicates that 18F-FDF may be the first feasible radiotracer validated for targeted PET/CT imaging of neoplastic tissues that express elevated levels of the COX-1 enzyme.
Md. Jashim Uddin et al. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer, ACS Omega (2019). DOI: 10.1021/acsomega.9b01093
Medical Xpress is a web-based medical and health news service that is part of the renowned Science X network.
Based on the years of experience as a Phys.org medical research channel, started in April 2011, Medical Xpress became a separate website.
Medical Xpress is a part of Science X network.
With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news,
the Science X network is one of the largest online communities for science-minded people.